Amphastar Pharmaceuticals
AMPH
279 hedge funds and large institutions have $1.72B invested in Amphastar Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 100 increasing their positions, 93 reducing their positions, and 32 closing their positions.
248% more call options, than puts
Call options by funds: $3.91M | Put options by funds: $1.12M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 32
25% more capital invested
Capital invested by funds: $1.37B → $1.72B (+$343M)
4% more funds holding
Funds holding: 269 → 279 (+10)
2.47% more ownership
Funds ownership: 70.27% → 72.74% (+2.5%)
8% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 93
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$23.7M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$19.5M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$15M |
| 4 |
Goldman Sachs
New York
|
+$13M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$9.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$21M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.65M |
| 3 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
-$7.83M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.61M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.18M |
AMPH Hedge Fund Activity: Q3 2024 in Review
279 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2024, worth a combined $1.72B — up 25% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new AMPH positions and 32 closed out — a net gain of 10 holders — while 100 added to existing stakes and 93 trimmed.
The largest buyer was Boston Trust Walden, opening a new position worth an estimated $23.7M. The largest seller was Millennium Management, cutting an estimated $21M.
- 279 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2024, up from 269 in Q2 2024.
- Funds reported $1.72B of Amphastar Pharmaceuticals stock for Q3 2024, up 25% quarter-over-quarter.
- 42 funds opened new Amphastar Pharmaceuticals positions in Q3 2024 and 32 closed out, a net change of +10 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2024 was Boston Trust Walden, an estimated $23.7M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2024 was Millennium Management, an estimated $21M sold.
Based on aggregated 13F filings for Q3 2024.